Clinical Trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Study acronym: BRE-10
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-29; most recent amendment 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2024-06-04
Trial Details
NCT Number NCT06441890
Lead Sponsor University of Illinois at Chicago
Conditions Breast Cancer, HER2-positive Breast Cancer
Enrollment 28 participants
Start Date 2024-12-05
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-14